Overview

Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease

Status:
Completed
Trial end date:
2021-04-30
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, single-arm 8-week investigation of Selegiline for treatment of EDS in PD patients.
Phase:
Phase 4
Details
Lead Sponsor:
Second Affiliated Hospital of Soochow University
Treatments:
Selegiline